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Abstract
Laminins (LM), basement membrane molecules and mediators of epithelial-stromal communication, are crucial in tissue
homeostasis. Inflammatory Bowel Diseases (IBD) are multifactorial pathologies where the microenvironment and in
particular LM play an important yet poorly understood role in tissue maintenance, and in cancer progression which
represents an inherent risk of IBD. Here we showed first that in human IBD colonic samples and in murine colitis the LMa1
and LMa5 chains are specifically and ectopically overexpressed with a concomitant nuclear p53 accumulation. Linked to this
observation, we provided a mechanism showing that p53 induces LMa1 expression at the promoter level by ChIP analysis
and this was confirmed by knockdown in cell transfection experiments. To mimic the human disease, we induced colitis and
colitis-associated cancer by chemical treatment (DSS) combined or not with a carcinogen (AOM) in transgenic mice
overexpressing LMa1 or LMa5 specifically in the intestine. We demonstrated that high LMa1 or LMa5 expression decreased
susceptibility towards experimentally DSS-induced colon inflammation as assessed by histological scoring and decrease of
pro-inflammatory cytokines. Yet in a pro-oncogenic context, we showed that LM would favor tumorigenesis as revealed by
enhanced tumor lesion formation in both LM transgenic mice. Altogether, our results showed that nuclear p53 and
associated overexpression of LMa1 and LMa5 protect tissue from inflammation. But in a mutation setting, the same LM
molecules favor progression of IBD into colitis-associated cancer. Our transgenic mice represent attractive new models to
acquire knowledge about the paradoxical effect of LM that mediate either tissue reparation or cancer according to the
microenvironment. In the early phases of IBD, reinforcing basement membrane stability/organization could be a promising
therapeutic approach.
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Introduction
Inflammatory bowel diseases (IBD) that comprise Crohn’s
disease (CD) and ulcerative colitis (UC) are multifactorial
pathologies where genetic and environmental factors initiate and
drive the pathology [1]. Chronic inflammation results from a
homeostatic imbalance, a phenomenon that also characterizes
tumor development [2]. IBD are characterized by various degrees
of inflammation of the intestine causing epithelial damage, among
others [3]. In general, the intestinal epithelium is able to repair
itself by the restitution of the epithelial layer. In response to
chronic ulceration, Ulcer Associated Cell Lineage glands (UACL;
[4]) expressing particular trefoil factor (TFF) and mucin molecules
[5–7] are found that appear to promote mucosal repair and
healing. Both forms of IBD, CD and UC, have an inherent risk of
progression into cancer with a similar occurrence in patients with
colonic CD to that with UC to develop colitis-associated cancer
[8,9]. Repeated tissue destruction and repair together with
oxidative damage can trigger mutagenesis and may serve as
cancer initiating events. In this process, a possible causative role
for mutated p53 tumor-suppressor gene is more and more evident.
Indeed, point mutations often resulting in a p53 gain of function,
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have been identified in neoplastic progression of UC [10–12] and
were shown to promote inflammation induced progression into
intestinal cancer [13].
Inflammatory responses are often associated with remodeling of
the extracellular matrix (ECM) as evidenced in wound healing and
tissue repair. Profound alterations in ECM expression and ECM
binding integrin adhesion receptors have been found in a number
of inflamed tissues [14,15]. The intestinal basement membrane
(BM) represents a specialized ECM network that separates
epithelial cells from the underlying connective tissue and is mainly
composed of collagen IV, laminins (LM), perlecan and nidogens.
The BM functions as a physical and chemical barrier. Several
human disorders result from or are associated with defects in BM
assembly or composition [16]. Two susceptibility loci linked to
ECM candidates, ECM1 and LAMB1, were found associated with
UC [17]. LM are a family of BM glycoproteins, each containing
an a-, b- and c- chain that assemble into characteristic
heterotrimers. LM, and in particular their a chains carrying the
cell binding domains, have been shown to be important for cell
adhesion, migration and proliferation; they are also known to
protect cells from apoptosis [16,18,19]. Immunodetection has
revealed that several LM isoforms exist in the human intestine,
including LM-111 (a1b1c1), LM-511 (a5b1c1) and LM-332
(a3b3c2) which show developmental and position specific
expression along the crypt-villus axis [20,21]. In IBD, inflamma-
tion leads to mucosal ulceration and subsequent tissue repair that
implies a continuous remodeling of the BM. Altogether, LM may
play an yet unknown instrumental role in the inflammation
response.
Limited data exist on the expression of epithelial BM
constituents in IBD. Altered immunoreactivity of BM constituents
has been described in IBD with an increase in LMa3 and LMa5
chains in the crypt region of inflamed segments of CD small
intestine in particular [22,23]. Among the genes identified by
mRNA profiling in inflamed UC colon, those associated with
tissue remodeling such as LAMA2 (encoding LMa2 chain) have
been reported to be overexpressed [24]. In vitro studies using
normal intestinal epithelial cells demonstrated that the two
inflammatory cytokines TNF-a and IFN-c synergistically modu-
late the expression and secretion of LMa5 and LMc2 chains [25].
Although sporadic, these data strengthen the notion that the
balance of different LM isoforms is crucial for tissue homeostasis
and imply that LM contribute to the inflammation response [26].
As the BM is an important actor of the intestinal barrier, we
addressed in the present study the role of LM in IBD. First, we
defined the expression of the major LM chains in colon specimens
from IBD patients and from a murine colitis model. By
immunofluorescence we showed a high expression of LMa1 and
LMa5 in the inflamed tissue that was associated with nuclear p53.
We addressed a potential role of p53 in inflammation-induced LM
expression and observed induction of LAMA1 in a p53 dependent
manner. We addressed the potential role of elevated LM
expression in IBD by inducing colitis in transgenic mice that
overexpressed LMa1 or LMa5 and demonstrated a protective
effect of these molecules against inflammation. However, in
context of carcinogenic mutations, high LMa1 or LMa5 levels
enhanced progression of chemically-induced colitis into cancer.
Materials and Methods
Human specimens and scoring of inflammation
Paraffin embedded tissue was obtained from 25 patients who
had undergone intestinal resection for acute CD of the colon and
from 7 patients with UC. As controls, non-inflammatory colon
samples for each patient as well as 15 colon samples distant from
colon carcinoma were analyzed. In parallel, adjacent samples for
immunofluorescence staining were embedded in Tissue-Tek
(Sakura, Labonord), immediately frozen on dry ice and kept at
280uC until later use. The inflammatory state was assessed by a
pathologist using the Riley score [27] and confirmed by
immunostaining for CD45, TLR4 (Figure S1) and for CD68
(not shown). IBD samples were obtained with the written informed
consent of patients prior to inclusion in the study. The Institutional
Review Board of the ‘‘Centre de Ressources Biologiques’’
(Association franc¸aise de normalisation: 2010/39043.2) of the
Hautepierre hospital (Strasbourg, France) has approved the study
on human samples.
Mouse models, genotyping and animal experiments
Methods about the generation of Tg-lama1 and Tg-lama5mice,
induction of colitis and of cancer-associated colitis as well as
cytokine measurements are provided in the Methods S1 section.
All procedures with animals were performed under a protocol
approved by the ‘‘Direction De´partementale de la Protection des
Populations’’ (agreement number: 67–261) and in accordance with
the ethical rules for the care and use of animals for research
(Comite´ d’e´thique pour l’experimentation animale, CEEA35 and
‘‘Institut national de la sante´ et de la recherche me´dicale’’ E67-
482-21 for the agreement of the animal house); all efforts were
made to minimize suffering.
Expression analysis at tissue and RNA levels
Antibodies used and primer sequences are listed in Table S1
and Table S2, respectively. Details concerning immunohisto-
chemistry, immunofluorescence, histology, assessment of apopto-
sis, RNA extraction and RT-qPCR are provided in the Methods
S1 section.
In vitro analysis of LM impact on p53 expression and on
NF-kB activity
HCT116 human colon carcinoma cells were plated onto 6-well
uncoated plates or plates coated with LM-111 or Caco-2 derived
LM-511 as described previously [28], and RNA was extracted
48 h, 72 h or 96 h after plating. RT-qPCR for p53 mRNA was
then performed with primers listed in Table S2. For Western blot
analysis, antibodies to p53 and to actin (internal control) are listed
in Table S1. To address a possible impact of LM on NF-kB
signaling, stable NF-kB reporting HT-29 cells [29] were seeded
onto 6-well control plates or onto plates coated with LM-111,
Caco-2 derived LM-511, human tenascin-C [30] or rat tail
collagen I at 5 mg/cm2. Luciferase activity was determined using
the Luciferase Assay System (Promega, France) according to the
manufacturer’s instructions. Details about cell culture conditions
are described in the Methods S1 section.
AFM measurements
HT29 epithelial cells expressing or not the LMa1 chain (H11
and B8T clones respectively [31]) were cultured for ten days. Cell-
derived matrices deposited on the cell culture dishes were isolated
following removal of the cells after a combined treatment of 1%Triton
X-100 with 10 mM EDTA [32]. AFM experiments were realized by
using a Bioscope Catalyst apparatus (Bruker Nano Surfaces Division,
Santa Barbara, CA USA). The silicon nitride cantilever with a spring
constant of 0.06 N.m21 and a 5 mm radius borosilicate particle
attached to the tip (Novascan Technologies, Ames, IA USA) was
navigated over the cell-derived matrix with approach/withdraw
velocities of 20.6 mm.s-1. Controlled deformations were applied to
Laminins in Colitis
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Figure 1. Inflammation response triggers expression of LMa1/a5 and nuclear p53 accumulation in human and murine colitis. (A)
Expression of the LMa5 and LMa1 chains in normal mucosa (control), in mild inflamed glands and around UACL from colon of patients with IBD.
Immunostaining for LMa5 in IBD samples is extended along the colonic glands with a strong staining at the deeper crypt region and is highly
expressed in UACL (arrows). LMa1 is detected selectively at the BM at the crypt bottom in IBD samples and in UACL while it is absent from uninflamed
regions; unspecific cytoplasmic immunoreactivity is seen in goblet cells (g). Inset: higher magnification of the deeper crypt region. (B) Expression of
LMa5 and LMa1 in cryosections of colon from control and DSS-treated mice. Note, as in human IBD, high expression of LMa5 and LMa1 was observed
in mouse colitis at the bottom of the colonic glands. (C) Nuclei of epithelial cells from inflamed colonic segments and in UACL of IBD patients were
positive for p53 while nuclei of the adjacent normal crypts showed rare p53-positive cells scattered within the glands. (D) Expression of p53 (green)
Laminins in Colitis
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the sample and the compressive feedback forces were measured
through cantilever deflection. On every culture dish, 25 areas were
probed in 3 different sample regions of 50650 mm each. The
Young’s-modulus (E) of the probed material was calculated by
fitting the contact part of the measured approach force curves to a
standard Hertz model for a spherical indenter (tip) of radius R.
Elasticity (E) of the probed material will reflect the mechanical
properties of the ECM deposited by the cells.
Transfection and infection with p53 or sh-TP53
For transfection experiments, HCT116 cells were grown onto
6-well plates (500 000 cells per well) and transfected with 3 mg of
either pCMV-Neo-Bam p53 wt, pCMV-Neo-Bam p53 V143A,
pCMV-Neo-Bam p53 R248W, pCMV-Neo-Bam p53 R249 S,
pCMV-Neo-Bam p53 R175 H, pCMV-Neo-Bam p53 R273 H,
or pCMV-Neo-Bam (Addgene, Cambridge, MA) using Jet-
PEITM reagent (PolyPlus Transfection, Illkirch, France) accord-
ing to the manufacturer’s instructions. RNA was extracted at
different time intervals (6 h, 48 h, 3 days or 4 days) after
transfection. For the 4 days time point of analysis, cells were re-
transfected at day 3.
Five different MISSIONR lentiviral shRNA clones for human
TP53 and a non-target shRNA control lentivirus (Sigma-Aldrich,
St Louis, MO) were tested in a first round in HCT116 cells.
Populations of lentiviral HCT116 infected cells were selected using
1 mg/ml puromycin (Invitrogen, France). Efficiency of TP53
inhibition was determined by RT-qPCR. Two stable HCT116 sh-
TP53(1) and sh-TP53(2) cell lines showing an inhibition of p53
expression of 86% and 92% respectively were selected for further
experiments. Cells were treated with irinotecan (20 mM, 48 h;
Roche Diagnostics, Meylan, France) and RNA extracted for
determination of LAMA1 transcripts by RT-qPCR.
Chromatin Immunoprecipitation Assay (ChIP)
The ChIP Assay was performed as recommended by the
manufacturer (EZ-Magna ChIPTM G kit, Millipore, France).
HCT116 cells were transfected by either pCMV-Neo-Bam or
pCMV-Neo-Bam-p53-wt 48 h before the experiment. Immuno-
precipitation was performed using two different anti-TP53
antibodies (Table S1) or normal mouse IgG as negative control.
Immunoprecipitated DNA was then used as a template for PCR.
Putative p53 binding sites on a 7 kb sequence of the LAMA1
promoter and on the first 5 kb of intron-1 were located using
MatInspector Professional program (www.genomatix.de). Primers
surrounding each p53 binding site are detailed in Table S2.
Statistical analysis
When data followed a Gaussian distribution, statistical analysis
was performed using the one sample t-test (TP53 gene transfec-
tion), the t-test (AFM) or the Anova’s test with Tukey’s multiple
comparison test (NF-kB reporter assay). Otherwise, the Mann
Whitney test (ELISA assay and irinotecan data) was used to verify
significance of the observed differences. All statistical analyses was
performed using the GraphPad software.
Results
Concomitant high expression of LMa1 and LMa5
correlates with nuclear p53 in colitis
A comprehensive analysis of LM distribution was conducted on
IBD human colon samples with chain specific LM antibodies.
Since in advanced stages of ulceration a detachment of the
epithelium together with the BM was observed, only specimens
with a mild inflammation could be investigated. Significant
differences in the spatial distribution of LMa1 and LMa5 chains
were detected at the BM level in all IBD tissues (CD and UC)
compared to control segments. While in normal colon mucosa, the
LMa5 chain presented a gradient of expression along the colonic
crypts and was absent at the bottom, a significant up-regulation
was obvious in the IBD samples (Figure 1A). This resembles an
expression pattern that had been described for the inflamed
proximal small intestine [22]. Concomitantly, there was an
induction in the crypt region of the LMa1 chain that is usually
absent from the BM in the normal adult colon (Figure 1A).
Distribution of LMa2, LMa4, LMb1, LMb2, LMc1 chains along
the BM region of colon glands was similar between IBD and
control tissues while the gradient of LMa3 and LMc2 was slightly
extended in IBD (Figure S2 and data not shown). Thus fine
examination by immunodetection allows us to show that LMa1
and LMa5 chains are ectopically and concomitantly expressed at
the bottom of the colonic crypts of IBD patients.
In CD and UC colon samples we also found the UACL glands
which are believed to play a role in tissue regeneration [4]. These
glands can be easily visualized by a stronger staining with PAS,
their typical appearance (epithelial cells with flat nuclei aligned
along the basal pole of the cells) and their particular expression
pattern of gastrointestinal mucins and trefoil peptides [4,6]
(Figure S3). We further characterized the molecular composition
of these UACL by using several markers (Figure S4, and data
summarized in Table S3). We found that UACL still expressed
epithelial characteristics, were positive for repair proteins and for
actors of the Wnt-signaling pathway. Interestingly, LMa1 and
LMa5 were strongly expressed around the UACL glands
(Figure 1A). This was different to LMa2 and LMa3 which were
irregularly and weakly expressed (Figure S2). Altogether, these
data, summarized in Figure 1E, suggest a functional role of the
LMa1 and LMa5 chains in IBD.
To experimentally mimic the inflammation phase of human
IBD, we induced DSS-driven colitis in mice. These mice presented
obvious signs of distal colonic inflammation that were identified
along the Swiss-roll of the colon (Figure S5). Within the inflamed
regions, areas with ectopic expression of LMa5 were observed at
the bottom of the crypts concomitant to a striking induction of
LMa1 (Figure 1B). These data corroborate our results in human
IBD, suggesting that the murine model phenocopies important
features of the human disease.
Integrins are the main cellular receptors known to bind the
LMa chains, in particular integrins a6b1 and a6b4 [19]. To
determine whether expression of these integrins is potentially
altered in IBD and murine colitis, we determined their expression
by immunofluorescence tissue staining. Whereas integrin b1
and LMa1 (red) in colon samples from DSS-treated mice. At day 3 after treatment, p53 immunoreactivity was present in numerous nuclei within
epithelial cells while LMa1 co-staining was weak; inset: enlarged area with nuclear p53 expression. At day 5, intense LMa1 staining was observed
surrounding weaker p53-positive glands (inset). (E) The diagram summarizes the distribution of the main LM chains found in normal colonic mucosa
(control), in mild inflamed glands and around UACL from colon of patients with IBD. Note that only the staining at the epithelial BM is schematically
represented for clarity. e: epithelial cells; lp: lamina propria; mm: muscularis mucosae; arrows: ectopic staining at crypt bottom and staining around
UACL. Scale bars: 50 mm (human), 25 mm (mouse).
doi:10.1371/journal.pone.0111336.g001
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Figure 2. Wild-type p53 induces LMa1 expression in epithelial cells via binding to the LAMA1 promoter. (A) HCT116 cells were seeded
on LM-111 or LM-511-enriched matrix. (Left) Endogenous p53 mRNA was quantified by RT-qPCR (normalized to GAPDH) and expressed as ratio
relative to the control (plastic dishes). The values are given as a mean +/2 SEM of 9 independent experiments which were pooled (n = 3 at 2 days;
n = 3 at 3 days; n = 3 at 4 days). (Right) Representative immunoblot of p53 and actin from HCT116 cells in the different conditions. Data show that LM
substrata do not activate endogenous expression of p53. (B) Relative mRNA expression of LM chains in HCT116 cells upon transfection with a TP53
vector assessed at different time points. Transcript levels were determined by RT-qPCR and normalized to GAPDH and are presented relative to the
control vector (n = 3 to 4 experiments, except for a1 at 6 h n= 6 and at 48 h n=8). Data show that wild-type (wt) p53 induces selectively and
progressively LMa1 mRNA levels. (C) Semiquantitative analysis of intracellular LMa1 after immunofluorescence staining of HCT116 cells (48 h of
irinotecan treatment). Note a 2.3-fold intracellular deposition of LMa1 in irinotecan-treated cells as compared to untreated cells (n = 15). (D)
Expression of LMa1 mRNA from two independent stable sh-TP53 HCT116 cell lines and in a sh-RNA control cell line, upon treatment with irinotecan.
After 48 h, relative mRNA expression of LMa1 was assessed by RT-qPCR and normalized to GAPDH; values are given as ratios relative to those found in
Laminins in Colitis
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e111336
expression was not altered in the inflamed tissue (data not shown),
a6b4 integrin was strongly expressed at the bottom of the colonic
crypts from mouse-colitis and IBD tissues as well as in the UACL.
This strong a6b4 integrin staining, located at the same place
where LMa1 and LMa5 are overexpressed, suggests that cells may
interact with both LM through this integrin (Figure S6).
During the ulceration process, cellular stress arises that typically
triggers a p53 response in order to guarantee genome integrity
[33]. Therefore we investigated the expression and location of p53
in human IBD and in murine colitis by immunohistochemistry
using antibodies that detect both wild-type and mutated p53 [34].
Histologically normal epithelium showed only sporadic nuclear
staining for p53. In contrast, most of the nuclei from UACL were
strongly positive for p53 and often neighboring glands presented
also some nuclear p53 expression (Figure 1C). Similar to the
human IBD tissue, p53 was also strongly expressed in nuclei of the
murine inflamed colon. This is particularly obvious at early stages
of inflammation (3 days after DSS treatment). At a later time
point, 5 days after DSS treatment, the number of p53-positive cells
decreased concomitantly with an increased LMa1 expression
(Figure 1 D).These data are consistent with a potential role of
p53 in regulating LAMA1 transcription upon inflammation.
LAMA1 expression is triggered by p53
First to exclude a potential regulation of p53 by LMa1 or by
LMa5, we cultured human colorectal HCT116 cells on LM-111
or LM-511-enriched matrices and p53 expression was determined
by RT-qPCR and immunoblotting. We noticed that neither of the
LM substrata had an impact on p53 mRNA and protein levels
(Figure 2A). To address the hypothesis of p53-dependent
regulation of LM, we performed transfection experiments. More
precisely, HCT116 cells were transfected with a wild type TP53
expression plasmid to examine whether such an ectopic expression
would result in increased expression of endogenous laminin
mRNA. Figure 2B shows that expression of LAMA1 mRNA in
HCT116 cells was increased 2.2-fold as early as 6 h and further
increased by 2.8- fold at 48 h after transfection with the p53
plasmid. Our study revealed also a time-dependent increase of
LAMA1 mRNA up to 4 days. In contrast to LMa1, mRNA levels
for LMa3, LMa5, LMb1 and LMc1 were not modified upon p53
overexpression (Figure 2B).
To address the role of endogenous p53 on LMa1 induction, the
topoisomerase I inhibitor irinotecan was used to trigger p53
expression [35] in HCT116 cells. Semi-quantitative immunode-
tection of the LMa1 protein in irinotecan-treated cells revealed a
2.3-fold increase of the p53 protein (Figure 2C). To further
confirm the p53-dependent LAMA1 induction, we determined
LAMA1 mRNA levels upon a knockdown of p53 by shRNA-
technology. We derived two stable HCT116 sh-TP53 cell lines
where the inhibition of p53 expression reached up to 92% (see
Materials and Methods) as compared to sh-control infected cells.
In these p53-deprived cells, irinotecan did not induce LAMA1
mRNA expression (Figure 2D).
As p53 mutants can be gain-of-function [36] we investigated
whether common human colorectal cancer-derived p53 mutants
([37] and http://p53.iarc.fr) also induced LAMA1 transcription.
Therefore, we expressed 5 different point mutants of p53 upon
transfection in HCT116 cells and determined LAMA1 mRNA
levels. We noticed that only wild-type but none of the tested p53
mutants induced LAMA1 expression (Figure 2E).
To address whether p53 induces LAMA1 transcription by
promoter binding, we searched for potential p53 binding sites in
the 39 upstream regulatory sequence of p53. By sequence analysis,
we identified seven putative p53 binding sites in the 7 kb LAMA1
sequence of the promoter and in the first 5 kb of intron-1
(Figure 2F). We used a ChIP assay to address whether p53 can
bind to the LAMA1 regulatory sequences. By using two different
p53 antibodies we found that these putative p53 binding sites were
amplified in the immunoprecipitates (Figure 2G). Thus, our
results suggest that the LAMA1 promoter has functional p53-
responsive elements and that LAMA1 expression could directly be
transactivated by p53. This is in contrast to LMa5 which is
expressed by a p53 independent mechanism.
Ectopically expressed LMa1 or LMa5 attenuates DSS
induced inflammation
So far we have described a specific upregulation of LMa1 and
LMa5 in IBD and in DSS-induced murine colitis. To assess
whether these LM regulate inflammation responses in the
intestinal epithelium, transgenic mice that overexpress either
LMa1 or LMa5 in the gut (under the intestine-specific villin
promoter) were generated ([38], Mammadova-Bach et al.,
submitted). Immunostaining revealed an ectopic expression of
LMa5 (Figure 3A) and of LMa1 (Figure 3B) at the bottom of
the colonic crypts in the respective Tg-lama5 and Tg-lama1
animals. The overall structure of the colon was not affected by
overexpression of either one of the LM chains (Figure 3A and
3B).
To provoke intestinal inflammation adult transgenic mice were
subjected to DSS. No further increase in LMa5 staining was noted
in colonic mucosa from DSS treated Tg-lama5 mice as compared
to the non-treated animals presumably due to its already high level
of expression in the non-inflamed situation (Figure 3A). This was
different to Tg-lama1 mice where DSS further increased
expression of LMa1 in the BM in two-thirds of the colonic crypts
as compared to one half in the DSS-treated wild-type animals
(Figure 3B versus Figure 1B). All DSS-treated animals pre-
sented signs of distal colitis with variable degree independently of
their genotype. Regions of strong inflammation corresponded to
significant ulcerations with detachment of the epithelium, presence
of distorted glands, abundant stroma and significant infiltration of
immune cells. Regions of mild inflammation were defined by an
almost normal architecture of the colonic glands in which the
epithelium was partially preserved or was in a regenerative state
(Figure S5). We used staining for tenascin-C (TNC) as marker of
inflammation [15], and observed higher TNC expression in the
ulcerative tissue (Figure S5). Such staining well corresponded to
the pattern of TNC expression in human CD or UC colon as
published [39], with increased expression at the mucosal surface
and in the lamina propria of IBD tissue, concomitantly with
the corresponding untreated cells (n = 3). In p53-deprived cells, irinotecan was unable to stimulate LMa1 expression. (E) Relative LAMA1 mRNA
expression in HCT116 cells following transfection with wt or mutants p53 (ratios calculated as stated above; n = 6). LMa1 mRNA were only activated
by wt p53. (F) Diagram showing the location of putative p53 binding motifs (sites 1 to 6) in the LAMA1 promoter 7 kb upstream of the transcription
site and in the 5 kb region of intron 1 (i). (G) Chromatin immunoprecipitation experiments. Chromatin was prepared from HCT116 cells transfected
with either the control (pCMV) or TP53 vector (p53). Cross-linked p53-DNA complexes were immunoprecipitated by either IgG (negative control) or
anti-p53 antibodies (DO1 or 1801) followed by PCR amplification using primers that flank the putative p53 binding sites. Input represents chromatin
before immunoprecipitation. Note that p53 binds to 7 candidate p53 binding sites. Bars represent mean +/2SEM; *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0111336.g002
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Figure 3. Laminins protect from inflammation. (A–B) Histological views of colon tissue (stained with PAS) and expression of LMa5 and LMa1 on
cryosections of colon from parental, Tg-lama5 or Tg-lama1 mice untreated or treated with DSS. This showed that both chains were ectopically
expressed in the glandular crypt region in the transgenic animals (arrows) and that LMa1 expression was further extended by DSS treatment. (C)
Laminins in Colitis
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increased fibronectin and a-smooth-muscle actin staining (Figure
S7).
To evaluate whether susceptibility to DSS-induced colitis was
potentially affected by the LMa1 and LMa5 expression levels,
histological grading of colitis was performed on the Swiss-roll
comprising the entire colon and rectum. A detailed assessment of
the inflammatory degree was performed. We noticed that the
mean score was significantly lower in transgenic mice (4.2 for Tg-
lama5; 4.0 for Tg-lama1) than in controls (6.8 for wt-lama5 mice;
7.2 for wt-lama1) (Figure 3C). Therefore, the concentrations of
pro-inflammatory cytokines were measured by ELISA in colonic
mucosal samples from inflamed parental and transgenic mice.
Levels of IL-1b, IL-6, IL-12 and TNFa, classical players
implicated in the inflammatory response of DSS-driven colitis,
were significantly decreased (up to 3.5-fold) in both Tg-lama5 and
Tg-lama1 colonic tissue in comparison to controls (Figure 3D).
NF-kB is a key player known to be implicated in inflammation
processes [40]. To test whether LM potentially attenuate NF-kB
signaling, HT-29 cells stably expressing a NF-kB reporter [29]
were plated on different ECM substrata and were stimulated with
TNFa. These experiments revealed that LM-511 was indeed able
to attenuate the TNFa-stimulated expression of the NF-kB
reporter (Figure S8A). As BM are part of the intestinal barrier,
we wondered whether an overexpression of a LM chain may
physically reinforce the BM. To test the hypothesis that increased
levels of LM enhance stiffness of the BM, we performed AFM
measurement on matrices deposited by colonic epithelial cells that
lacked or expressed the LMa1 chain. Indeed we found that a cell-
derived matrix containing the LMa1 chain showed a higher
stiffness suggesting a physical BM strenghtening (Figure S8B).
Altogether, our data showed that colon inflammation was
attenuated in transgenic LMa1 or LMa5 mice as assessed by the
histological scoring of inflammation and by decreased expression
of inflammatory cytokines, involving regulation of the NF-kB
signaling pathway and BM stiffening.
Impact of LMa1 and LMa5 overexpression on murine
colitis-associated tumorigenesis
Patients with IBD are at increased risk of developing colitis-
associated cancer [8,41] upon acquisition of oncogenic mutations
[42]. Based on our results that had shown that ectopic expression
of LMa1 promoted colon tumorigenesis ([31]; Mammadova-Bach
et al. submitted) and that high LMa1 and LMa5 expression
attenuates colitis associated inflammation (this study) we wondered
what impact these LM have on progression of colitis into cancer.
Therefore, we first exposed control and transgenic mice to a
combined AOM/DSS treatment that, with a short latency period,
led to the development of inflammation-driven colorectal tumors
due to AOM carcinogen induced mutations [43]. Analysis was
performed 3 days after the last DSS treatment (see Figure 4A)
revealing appearance of dysplastic precursor lesions. After
histological examination of the Swiss-rolls we found dysplasia
and in situ carcinomas that occurred at about a 2-fold higher rate
in the colon/rectum region of Tg-lama1 mice than in controls
(Figure 4B). The same tendency was also observed in Tg-lama5
mice although the increase was not statistically significant
(p = 0.1336; n= 4; Figure S9A). To mimic chronic inflammation
that occurs in IBD, we then performed a second colitis-associated
cancer model based on cyclic administration of DSS (Figure 4A).
Comparable to the AOM/DSS model, LMa1 transgenic mice
presented also an about 2-fold higher incidence of tumors.
Whatever the protocol used, all lesions (dysplasia and in situ
carcinomas) were characterized by high expression of LMa1 and
LMa5 in the BM and by nuclear accumulation of p53 in the
epithelial cells (Figure 4C and Figure S9B).
Discussion
LM are major components of epithelial BM playing an
important role in tissue homeostasis but knowledge regarding
their involvement in gastrointestinal pathologies including IBD
and colitis-associated cancer remains very limited [26]. The data
presented here show that LM can impact on the microenviron-
mental response to inflammation in the intestine and likely
participate in the regeneration process. This is emphasized by an
increased LMa1 and LMa5 expression in colon tissues from IBD
patients and from DSS-driven colitis in mice. Inflammation was
accompanied by a nuclear accumulation of p53 and changes in
cell identity/properties as manifested particularly by the presence
of UACL in IBD. We provided a mechanistic link between p53
and LM by demonstrating that p53 transactivates LAMA1
expression through promoter binding. We further showed an
attenuated response to DSS-induced inflammation in transgenic
mice overexpressing either the LMa1 or LMa5 chain. Yet,
overexpression of the same LM molecules could participate in the
progression of IBD into colitis-associated cancer upon acquisition
of oncogenic mutations as exemplified by AOM/DSS or chronic
DSS treated transgenic mice. Our data point to the distinct,
sometimes opposing properties of LM, reinforcing their described
potential dual functions [44].
Here we showed that in upon inflammation, both LMa1 and
LMa5 chains are overexpressed using human IBD and murine
colitis specimens. Furthermore we demonstrated in transgenic
mice that both LM attenuate DSS-induced inflammation as shown
by a reduced inflammatory score and a decreased expression of
pro-inflammatory cytokines. These data suggest that a1/a5 chain-
containing LM potentially play a role in the IBD disease by
limiting colitis. At present time, it was not possible to determine
the precise expressed LM isoform, as nobody has managed so far
to isolate such thin in vivo BM. Yet, the functionality of the LM
isoform is known to be mainly mediated by the LMa chain though
interaction with cell membrane receptors [45]. Here we provided
arguments showing that LMa1 and LMa5 act probably via two
distinct (p53 dependent and independent) mechanisms. We first
examined a potential involvement of NF-kB because of its
documented role in intestinal inflammation [46]. We provided
evidence that LM-511 (a5-containing LM) is indeed able to
attenuate the TNFa-stimulated expression of the NF-kB reporter.
Since LM are constituents of BM which serve as physical and
chemical barriers in epithelial tissues it is also possible that their
increased abundance in IBD strengthens the BM barrier. Indeed,
a cell-derived matrix that contains the LMa1 chain showed an
increased stiffness in vitro. Altered mechanical properties of LMa1
Inflammatory scores (mean +/2 SEM; n = 5) assessed on the Swiss-roll of the colon and rectum of transgenic lama5 and lama1 animals (black
columns) as compared to controls (grey columns), all treated with DSS. (D) Levels of pro-inflammatory cytokines (mean +/2 SEM; n= 6) measured by
ELISA in protein extracts from distal colon of DSS-treated parental (grey columns) and DSS-Tg-lama1 or DSS-Tg-lama5 (black columns) mice. Data
were normalized to the mean of parental values as levels of cytokines turned out to be mouse strain-dependent. Statistical differences were
compared to parental mice. e: epithelial cells; lp: lamina propria; mm: muscularis mucosae. Nuclei are visualized with DAPI. *p,0.05, **p,0.01. Scale
bars: 50 mm.
doi:10.1371/journal.pone.0111336.g003
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Figure 4. Colitis-associated tumor development is increased in transgenic mice overexpressing LMa1. (A) Schematic overview of the
AOM/DSS and of the cyclic DSS protocols. (B) Control and transgenic mice treated with AOM/DSS or with cyclic DSS develop different types of lesions
among them dysplasia and in situ carcinomas that were quantified. Tg-lama1 animals develop more tumors than controls when submitted to the
treatments (n = 7, *p,0.05 for AOM/DSS; n = 7, *p,0.05 for cyclic DSS). (C) Dysplasia and an in situ carcinoma are shown by hematoxylin-eosin
staining (HE). Glands in these lesions are strongly positive for LMa1 (red), LMa5 (green, lower panels) and present nuclear p53 (green, middle panels).
Nuclei were visualized with DAPI. e: epithelial cells; m: muscle; c: cancer cells; s: stroma; arrows: BM area. Scale bars: 50 mm.
doi:10.1371/journal.pone.0111336.g004
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rich-BM may contribute to protection from inflammation. This
hypothesis could be verified in the future owing to the recently
developed technology of AFM on isolated BM [47]. Reinforcing
BM stability/organization could be a promising therapeutic
approach in the early phases of IBD. This might be feasible as a
LM substitution ‘‘therapy’’ was already applied to the LMa2
chain-deficient mice where transgenic expression or systemic
administration of LM-111 reduced muscular dystrophy [48].
Linked to IBD, reintroduction of colon organoids (embedded in
the LM-containing Matrigel) into superficially damaged mouse
colon is now feasible [49].
LM could also play a role in tissue restitution as there is some
evidence from in vitro studies that they promote ‘‘wound’’ closure
of disrupted epithelial cell monolayers [50] which is important in
tissue rebuilding. This process may be further enhanced by growth
factors such as TGFb and TNFa which have been shown to
stimulate LM expression and secretion [25,51]. In most IBD colon
samples we found LMa1 and LMa5 to be highly expressed around
UACL that are morphologically and functionally different from
the normal colonic crypts. UACL are characterized by defined
expression patterns of TFF and mucin molecules [6,7] and we
indeed observed this unusual molecular composition of UACL ([6]
and present data) supporting the notion that they participate to
repair processes as strengthened previously in the literature [52].
We also found modifications in the expression of transcription
factors that play a role in cell fate decision such as Sox9, Pdx1 and
Cdx2 which is in accordance to the changes in the pattern of
cellular differentiation documented in human IBD [53]. To date,
the physiological relevance of this observation remains unclear.
We wondered why and how IBD glands are overexpressing
LMa1 and LMa5 and we found that interestingly they also
expressed nuclear p53. During the ulceration process, cellular
stress and DNA damage occur that typically trigger a p53 response
in order to guarantee genome integrity. It is known that active p53
induces a transient cell cycle arrest (absence of Ki67 positive and
apoptotic cells in UACL, Figure S4) enabling the cell to activate
enzymatic DNA repair systems [54]. In this context, we
investigated expression of genes implicated in p53 linked DNA
repair such as 53BP1, Mlh1, Msh2 and cH2AX (Table S3). The
first three proteins were expressed in UACL and neighboring
glands reflecting a normal response to inflammation and
confirming a functional role of nuclear p53 in IBD, while cH2AX
was not increased indicative of the absence of DNA double strand
lesions.
Besides its role in cell cycle regulation and DNA repair, we
suggest a novel function of p53 during IBD by modifying BM
properties. Our results suggest that p53 triggers LMa1 expression
by binding to the promoter (as evidenced by ChIP assays). This
finding does not exclude the possibility that p53 potentially
cooperates with other transcriptional regulators such as SP1 that
by itself has been shown to induce the murine lama1 gene [55].
One can postulate that LMa1 could have an indirect positive
impact on BM formation by triggering expression of other BM
molecules at least in vivo. Indeed our present data showed that
LMa5 upregulation was independent of p53 and we previously
demonstrated that exogenous expression of LMa1 in grafted
intestinal HT29 cells had caused increased expression of LMa5
[31]. The concomitant increased of integrin a6b4 ([31] and
present study) would argue for a fortified interaction of colonic
epithelial cells with their BM. Yet, although LM-111 and LM-511
have been shown to form independent networks under physiolog-
ical conditions [45,56], their possible connections and timing of
assembly into the BM in IBD and associated-cancer will need to be
addressed in the future.
Upon dysregulated ulceration/repair cycles and acquisition of
oncogenic alterations, IBD could degenerate into cancer [57]. To
mimic IBD-associated cancer we developed two models of colitis-
associated tumorigenesis in transgenic LM-overexpressing mice.
We showed that chronic DSS- and AOM/DSS-induced tumor
formation was enhanced in the intestine of LMa1 transgenic mice
suggesting that in a carcinogenic context LMa1 favors tumori-
genesis. Mutations of p53 have been described as an early event in
colitis-associated cancer [42] and more recently it was also
demonstrated that mutated p53 promotes progression of IBD into
associated colon cancer [13]. In the murine model we found
nuclear p53 both in dysplasia and in tumors. The status of p53,
whether mutated or not, is unknown in our samples. Whether and
how ectopic LMa1 and LMa5 are organized into BM in IBD and
in particular during colitis associated cancer is important to
elucidate and might provide novel means to fight cancer.
Taken together our results showed that the forced expression of
LMa1 and LMa5 (which are elevated in human colitis) protected
Figure 5. Important role of p53 in regulating LM expression in IBD and colitis-associated cancer. We propose the following scenario
where inflammation triggers nuclear accumulation of p53 that transactivates expression of LMa1 and its deposition to the BM concomitantly to that
of LMa5. Overexpression of LMa5 in response to inflammation is a p53 independent mechanism. In a chronically inflamed microenvironment highly
expressed LMa1 and LMa5 may provide physical barrier function resulting in attenuated inflammation as demonstrated in transgenic mice. Yet, high
LMa1 and LMa5 in a carcinogenic setting subsequent to chronic colitis may contribute to a pro-tumorigenic microenvironment.
doi:10.1371/journal.pone.0111336.g005
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against DSS-induced inflammation. But in carcinogenic conditions
the same LM molecules accelerate colitis-associated tumorigenesis
(Figure 5). More knowledge about the switch from good
(reparation) into evil (cancer) is required where our transgenic
mice represent attractive new models. In the early phases of IBD,
reinforcing BM stability may be a promising therapeutic
approach.
Supporting Information
Figure S1 Assessment of the inflammatory scores in
Crohn’s disease and ulcerative colitis. (A) The macroscopic
appearances of the colonic mucosa after hematoxylin-eosin
staining were graded using the Riley’s score on 25 Crohn patients
and 7 Ulcerative colitis patients giving a mean value ranging from
8.3 to 8.6 while control samples never exceed 1.4. (B)
Inflammation was further confirmed by immunohistochemistry
showing strong CD45 and TLR4 reactivity in samples from CD
patients. Scale bars: 25 mm.
(TIF)
Figure S2 Spatial distribution of LMa2, LMa3 and
LMa4 chains in non-inflamed and inflamed colon tissues
from IBD patients. Representative immunofluorescence pic-
tures for LMa2, LMa3 and LMa4 showing the presence of LMa2
in crypt glands (arrowheads) and around UACL for LMa2 and
LMa3. Note that anti-LMa4 antibodies stained the myofibroblasts
(inset) located underneath the BM as well as the muscularis
mucosae. Nuclei are visualized with DAPI. e: epithelial cells; lp:
lamina propria; mm: muscularis mucosae; g: aspecific staining of
mucus cells; arrows: BM staining around UACL. Scale bar:
50 mm.
(TIF)
Figure S3 Characteristic features of the UACL found in
IBD patients. (A) The UACL were identified as glandular
structures strongly stained in magenta with PAS as compared to
the normal colonic glands; they were characterized by elongated
flat nuclei at the basal pole of the cell (inset; staining with
hematoxylin-eosin). (B) The cells that composed the UACL
showed immunoreactivity for MU5AC (inset) and MUC6, while
no reactivity was observed for MUC2 or Cdx2 as compared to
normal colonic areas; UACL are positive or negative for TFF1
and TFF3 depending on their location within the mucosa. Nuclei
are visualized with DAPI. Arrows point to the UACL. * points to
morphologically-defined atypical glands slightly stained for TFF1.
Scale bars: 50 mm.
(TIF)
Figure S4 Immunohistochemical characterization of
the UACL lineage including proliferation, apoptosis, cell
identity markers and repair proteins. The cells that
composed the UACL in IBD do not proliferate (negative
immunostaining for Ki67) and do not reveal sign of apoptosis
(TUNEL assay). They still show positive immunoreactivity for
epithelial markers (E-cadherin, cytokeratin-19) and display
expression of repair proteins (Mlh1 and Msh2). Nuclei of the
UACL are positive for actors of the Wnt pathway such as b-
catenin, c-myc and Sox9. The presence of the Pdx1 transcription
factor in the nuclei of UACL combined to the mucin and TFF
profiles (depicted in Figure S3) are features of gastro-duodenal
metaplasia. Arrows point to the UACL. Scale bar: 50 mm.
(TIF)
Figure S5 Analysis of inflammation on Swiss-rolls of the
distal intestine. Representative picture (HE) of a cryosection
throughout a Swiss-roll of colon and rectum from a wt mouse
treated with DSS; the proximal colon is located on the external
part of the Swiss-roll while the rectum is at the centre. (1–3)
Enlargement of representative zones found along the Swiss-roll: (1)
area corresponding to strong signs of ulceration with distorted/
altered glands where there was accumulation of tenascin-C (TNC)
in the stroma and in the apical region of the glands; (2) region of
mild inflammation where the colonic mucosa was partially
preserved showing also an increased TNC staining in the stroma;
(3) non-inflamed mucosa showing the typical TNC staining at the
upper part of the gland.
(TIF)
Figure S6 Expression of integrin a6 and b4 subunits in
human and mouse presenting colitis. (A) In human, IBD
colon samples presented an increased staining of a6 and b4
integrins at the bottom of the gland and a strong immunoreactivity
mostly confined to the basal part of epithelial cells from the UACL
in contrast to normal adjacent glands (a) where lateral staining was
also observed. (B) Such increased staining of a6 and b4 integrins
was also obvious in murine colitis tissue. Nuclei are visualized with
DAPI. e: epithelial cells; lp: lamina propria. Scale bars: 50 mm.
(TIF)
Figure S7 Analysis of the stroma and myofibroblasts in
colon from IBD patients. Representative micrographs from
colonic control, IBD specimens and from UACL obtained after
immunofluorescence staining for TNC, fibronectin (FN) or by
immunohistochemistry for the detection of a-smooth muscle actin
(a-SM actin, marker of activated fibroblasts). TNC staining was
increased at the mucosal surface and in the lamina propria
(asterisk) of IBD samples, especially in UC patients as well as
around the UACL. Similarly, FN and a-SM actin were also
upregulated in the stromal compartment of IBD samples as well as
around UACL. Nuclei are visualized with DAPI. e: epithelial cells;
lp: lamina propria; mm: muscularis mucosae; arrows: UACL Scale
bars: 50 mm.
(TIF)
Figure S8 LM-511 inhibits the inflammatory response
to TNFa via NF-kB and LM-111 reinforces the BM by
increasing its stiffness. (A) NF-kB reporting HT-29 cells were
cultured with or without TNFa on different matrix substrata and
compared to dishes without matrix (no coating). The values are
given as fold change in luciferase activity (ratio with TNFa/
without TNFa; mean +/2 SEM from 6 independent experi-
ments). Note that LM-511 inhibits the TNFa-stimulated expres-
sion of the reporter gene assessed by luciferase activity as
compared to other ECM molecules. (B) Young’s modulus (E, in
Pa) was calculated after AFM measurements of the cell-derived
matrix expressing (+LMa1) or not (control) the LMa1 chain
reflecting its stiffness. The values are given as mean +/2 SEM
from 25 measurements of 3 different areas of 50650 mm in each
dish. Note that the stiffness of the cell-derived matrix expressing
LMa1 was statistically increased as compared to the LMa1-
deprived matrix. Coll. I: collagen I; ***p,0.001.
(TIF)
Figure S9 Colitis-associated tumor development in
transgenic overexpressing LM mice. (A) Dysplasia and
in situ carcinoma were determined in Swiss-roll from Tg-lama5
and control mice upon treatment with AOM/DSS. Similarly to
Tg-lama1 mice more tumors have been found in Tg-lama5 colon
than control animals although not statistically significant (mean
+/2 SEM; n= 4; p = 0.1336). Note that Tg-lama5 and control
littermates develop fewer lesions than Tg-lama1 (see Figure 4)
probably due to genetic background differences. (B) Likewise to
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the AOM/DSS treatment, dysplasia and in situ carcinoma have
been induced by cyclic DSS treatment in Tg-lama1 mice. The
lesions presented high LMa1 and LMa5 expression at the
interface between cancer cells and stroma. p53 staining was
obvious in numerous nuclei. e: epithelial cells; c: cancer cells;
arrows: BM area.
(TIF)
Table S1 Description of the antibodies used.
(PDF)
Table S2 Sequences of the primers used for genotyping,
RT-qPCR and chromatin immunoprecipitation.
(PDF)
Table S3 List of the markers examined to characterize
the UACL.
(PDF)
Methods S1 Mouse models; Histology and immunode-
tection; Cell culture conditions; quantitative RT-PCR.
(PDF)
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